ASX:DXB Dimerix (DXB) Stock Price, News & Analysis → How a $0.25 cent option contract makes my top traders feel (From DTI) (Ad) Free DXB Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend Yield5.16%Price TargetN/A Stock AnalysisStock Analysis Get Dimerix alerts: Email Address Ad Insider FinancialThousands of investors use this no cost solution | Do you? In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.Simply tap here now to subscribe and start getting "Insider Financial Advantage" About DimerixDimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs. It develops DMX-200, a Phase 3 clinical trial for focal segmental glomerulosclerosis disease; DMX-200 for diabetic kidney disease; and DMX-700 for chronic obstructive pulmonary disease, as well as develops proprietary receptor- HIT assay technology. The company is headquartered in Fitzroy, Australia.Read More Ad Insider FinancialThousands of investors use this no cost solution | Do you? In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.Simply tap here now to subscribe and start getting "Insider Financial Advantage" DXB Stock News HeadlinesApril 16, 2024 | afr.comDimerix LimitedApril 8, 2024 | finance.yahoo.comCompanies Like Dimerix (ASX:DXB) Could Be Quite RiskyApril 26, 2024 | Prosper Trading Academy (Ad)These AI trades triggered this morning (545% return)If you think a market crash is possible in 2024, I don't know why you're not using this yet.April 8, 2024 | finance.yahoo.comInvestors ignore increasing losses at Dimerix (ASX:DXB) as stock jumps 236% this past weekApril 8, 2024 | finance.yahoo.comShareholders Will Likely Find Dimerix Limited's (ASX:DXB) CEO Compensation AcceptableApril 8, 2024 | finance.yahoo.comCalculating The Intrinsic Value Of Dimerix Limited (ASX:DXB)August 29, 2022 | finance.yahoo.comTrade Alert: Peter Meurs At Dimerix Limited (ASX:DXB), Has Just Spent AU$3.5m Buying 66% More SharesAugust 29, 2022 | finance.yahoo.comHere's Why We're Watching Dimerix's (ASX:DXB) Cash Burn SituationApril 26, 2024 | Prosper Trading Academy (Ad)These AI trades triggered this morning (545% return)If you think a market crash is possible in 2024, I don't know why you're not using this yet.August 29, 2022 | finance.yahoo.comWe Think Dimerix (ASX:DXB) Needs To Drive Business Growth CarefullySee More Headlines Receive DXB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dimerix and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:DXB CUSIPN/A CIKN/A Webdimerix.com Phone1.212.250.8024FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,870,000.00 Net Margins-119.20% Pretax MarginN/A Return on Equity-330.96% Return on Assets-63.63% Debt Debt-to-Equity Ratio83.19 Current Ratio4.84 Quick Ratio7.91 Sales & Book Value Annual Sales$9.12 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares548,600,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta0.51 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Nina Webster B.Sc.M.B.A., M.IP.Law, MBA, Ph.D., CEO, MD & DirectorMr. Hamish George B.Com.C.A., CFO & Company SecretaryDr. David Everett Fuller BPharm (Age 60)M.D., MBBS, Chief Medical Officer Mr. Kevin Donald George Pfleger BA (Hons)MA, Ph.D., Chief Scientific AdvisorMr. Robert ShepherdChief Commercialisation OfficerKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF45525 (CUR.TO)TSE:CUR60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFView All CompetitorsInsidersNina WebsterBought 33,000 shares on 3/27/2024Total: $10,230.00 ($0.31/share)Nina WebsterSold 93,750 sharesTotal: $11,812.50 ($0.13/share)Nina WebsterSold 2,052,956 sharesTotal: $283,307.93 ($0.14/share)Sonia PoliSold 11,334 sharesTotal: $4,533.60 ($0.40/share)Nina WebsterSold 187,500 sharesTotal: $15,000.00 ($0.08/share) This page (ASX:DXB) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressBetter than Bitcoin? The Biotech Stock with 46,751% PotentialBehind the MarketsEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dimerix Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
